Haisco’s Prostate Cancer Drug HSK38008 and DPP-4 Inhibitor HSK7653 Accepted for Review
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that the clinical trial filing for...
SHE: 002653
Haisco’s EGFR-PROTAC HSK40118 Accepted for Review by China’s NMPA
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its clinical trial filing...
Haisco’s HSK31858 Gains Ethical Approval for Phase II Study in NCFBE
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its drug candidate HSK31858...
Haisco’s HSK16149 Accepted for Review by NMPA for Diabetic Neuropathic Pain
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that a market approval filing...
Haisco Pharma’s Ciprofol Injection Gains NMPA Approval for Gynecology Use
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving another marketing approval from...